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Abstract
Background: Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in
sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence
opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the
aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development.
Methods: A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar,
eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of
chronic liver disease. The baseline evaluation included: (i) a semi-structured interview designed to obtain information
about the ingestion of alcohol, herbal medicines and local recreational drugs such as khat (Catha edulis); (ii) clinical
examination; (iii) extensive laboratory testing; and, (iv) abdominal ultrasonography.
Results: One-hundred-and-fifty patients with CLD (men 72.0%; median age 30 [interquartile range 25–40] years) were
included. CLD was attributed to chronic HBV infection in 55 (36.7%) individuals; other aetiological agents were
identified in a further 12 (8.0%). No aetiological factors were identified in the remaining 83 (55.3%) patients. The overall
prevalence of daily khat use was 78.0%, while alcohol abuse, defined as > 20 g/day in women and > 30 g/day in men,
was rare (2.0%). Histological features of toxic liver injury were observed in a subset of patients with unexplained liver
injury who underwent liver biopsy.
Conclusion: The aetiology of CLD in eastern Ethiopia is largely unexplained. The widespread use of khat in the region,
together with histopathological findings indicating toxic liver injury, suggests an association which warrants further
investigation.
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Background
‘Chronic liver disease’ (CLD) is the term used to describe
disordered liver function lasting for six or more months.
It results from a process of progressive destruction and
regeneration of the liver parenchyma and encompasses a
wide range of liver pathologies including: chronic
hepatitis, cirrhosis and hepatocellular carcinoma. CLD is
a major cause of morbidity and mortality, and was re-
sponsible for an estimated 1.3 million deaths worldwide
in 2015 [1]. The commonest causes of CLD are chronic
infection with hepatitis B (HBV) or C (HCV), alcohol mis-
use and non-alcoholic fatty liver disease (NAFLD) [2].
Ethiopia is a low-income country in East Africa with a
population of nearly 100 million [3]. The prevalence of
CLD in Ethiopia is largely unknown but is assumed to
be high [4]. The estimated seroprevalence of hepatitis B
surface antigen (HBsAg) in Ethiopia is 6.0% [5] and of
HCV-antibody (anti-HCV) 3.1% [6]. Although these data
are extracted predominantly from institution-based
studies and may not be representative of the situation
nationwide, chronic HBV infection is thought to be a
major cause of CLD in this region [4].
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Community-based, longitudinal studies have been
undertaken in several rural areas of Ethiopia, in recent
years, using a verbal autopsy method to assign causes of
death [7–9]. CLD was the leading cause of death in the
age group 15–49 years in Kersa in eastern Ethiopia
(13.7%) [9] and in Butajira in central Ethiopia (11.3%)
[7]. In contrast, CLD was the cause of death in only
3.5% of adults of the same age in Kilte Awlalo in north-
ern Ethiopia [8]. One suggested explanation for this dif-
ference is the relative availability of khat (Catha edulis),
an indigenous plant which is chewed for its psychotropic
effects. Khat chewing has been associated with the devel-
opment of CLD [10]; its use is widespread in eastern
[11] and south-central Ethiopia [12] but much less so in
northern parts of the country [13].
One of the most important aspects of CLD prevention
is the identification and management of potential risk
factors. Public health efforts to reduce the toll of CLD in
Ethiopia and other countries in sub-Saharan Africa will
be considerably hampered if information on avoidable or
treatable risk factors is unavailable. Thus, the aims of
this study were to explore the aetiological spectrum of
CLD in eastern Ethiopia and to identify plausible under-
lying risk factors for CLD using a hospital-based cross-
sectional design.
Methods
Study setting and participants
A cross-sectional study of indigenous adults, aged
≥18 years, presenting for the first time with features of
CLD was undertaken in two governmental hospitals in
Harar, eastern Ethiopia between April 2015 and April
2016. CLD was defined as: (i) the presence of clinical
features suggestive of decompensated liver disease viz.
ascites, jaundice and/or hepatic encephalopathy; and (ii)
the presence, on ultrasound, of hepatic parenchyma het-
erogeneity and/or surface irregularity. Patients present-
ing with severe acute hepatitis defined as liver injury of
< 6 weeks duration, serum alanine aminotransferase
(ALT) activity of > 100 U/L and the absence of coars-
ened echotexture and surface irregularity on ultrasonog-
raphy, were excluded. Also excluded were patients with
liver dysfunction secondary to comorbidities viz. con-
gestive cardiac failure, biliary obstruction and septicae-
mia. Patients who had previously diagnosed CLD were
excluded since they might represent a subgroup with
more severe liver disease, or might have altered their risk
habits in response to previous medical advice.
Patient assessment
Suitable patients presenting to the regional Hiwot Fana
Specialized University Hospital, and the local Jugal
Hospital underwent a semi-structured interview by local
nurses fluent in their mother tongue. Demographic data
were recorded and potential risk factors for CLD were
explored. Information on past and current use of alcohol
was obtained and quantified in grams. Daily alcohol con-
sumption of > 20 g in women and > 30 g in men, for a
minimum period of 6 months, was classified as alcohol
misuse. Information on khat usage was obtained using a
visual analogue scale and quantified in grams. The fre-
quency and duration of khat use in years was used to
classify lifetime khat exposure as khat-years. Approxi-
mately 100–300 g of fresh khat leaves are chewed in a
typical session [14]; thus, one khat-year was defined as
daily use of 200 g of fresh khat for 1 year.
Clinical examination was undertaken using a pre-
specified proforma.
Laboratory tests
Blood was collected by venous puncture for immediate
processing; serum and plasma were separated and stored
in aliquots at − 20 °C until transported on ice/dry ice for
analysis either in Ethiopia or Norway. Full blood counts
were performed using a KX-21 N™ haematology analyser
(Sysmex, Kobe, Japan). Standard biochemical tests were
analysed using a semi-automatic biochemistry analyser
DR-7000D (DIRUI, Changchun, China) and HumaLyzer
3000 (HUMAN, Wiesbaden, Germany). The serum
aspartate aminotransferase (AST) to platelet ratio index
(APRI) was calculated as
AST ðU=LÞ
upper reference range of AST ðU=LÞ
platelet count ð109=LÞ  100
[15], using a threshold of 0.7 as indicator of significant
fibrosis [16]. The Fibrosis-4 (FIB-4) score was calculated
as age ðyearsÞ x AST ðU=LÞ
platelet count ð109=LÞ x
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ALT ðU=LÞ
p , using a threshold of 3.25
to indicate advanced fibrosis/cirrhosis [17].
HBsAg was measured using the rapid diagnostic test
(RDT) Determine™ (Alere, Waltham, MA, USA); anti-
HCV was measured using the SD BIOLINE HCV RDT
(Standard Diagnostics, Yongin-si, Republic of Korea).
Confirmatory testing of HBsAg and anti-HCV was
undertaken using enzyme-linked immunosorbent assays
(Elisys Uno, HUMAN, Wiesbaden, Germany; or Archi-
tect, Abbott Diagnostics, IL, USA). HBV DNA and HCV
RNA were measured in patients who tested positive for
HBsAg or anti-HCV by polymerase chain reaction using
RealTime HBV, m2000 system (Abbott Molecular,
Abbott Park, IL, USA). Plasma was analysed for hepatitis
D virus (HDV) antigen and HDV-antibody using the
ETI-DELTAK-2 and ETI-AB-DELTAK-2 assay (DiaSorin,
Turin, Italy), respectively.
Human immunodeficiency virus (HIV) screening was
performed using the KHB HIV (1 + 2) Antibody RDT
(Shanghai Kehua Bio-Engineering, Shanghai, China) and
confirmed using the HIV 1/2 STAT-PAK® RDT (Chem-
bio Diagnostics, Medford, NY, USA). Malaria screening
was performed using the SD BIOLINE Malaria Ag P.f/
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P.v RDT (Standard Diagnostics) and confirmed by mi-
croscopy of blood smears.
Serum was analysed for immunoglobulin G using the
IMMAGE® 800 Immunochemistry System (Beckman
Coulter, Brea, CA, USA). Serum iron and transferrin
concentrations were quantified using ARCHITECT
ci16200 (Abbott Diagnostics). Total iron binding
capacity (TIBC) was calculated as 25.1 × serum transfer-
rin (g/L) and transferrin saturation as serum iron ðμmol=LÞTIBC ðμmol=LÞ 100%.
Anti-nuclear, anti-mitochondrial and anti-actin anti-
bodies were analysed by the Phadia™250 Laboratory
system (Thermo Fisher Scientific, Waltham, MA, USA)
using the EliA™ Symphony assay (Phadia, Freiburg,
Germany), QUANTA Lite® M2 EP (MIT3) and
QUANTA Lite® Actin IgG (Inova Diagnostics, San
Diego, CA, USA).
A stool sample was collected and five thick smears
processed according to a modified Kato-Katz technique
using 41.7-mg templates for detection of the ova of
Schistosoma mansoni [18].
Patients who, after initial screening, appeared to have
unexplained CLD underwent more extensive testing in-
cluding: measurement of serum alpha-1-antitrypsin and
caeruloplasmin concentrations using the IMMAGE® 800
Immunochemistry System (Beckman Coulter); high iron
Fe (HFE) genotyping, if the serum transferrin saturation
was increased above 50%, without obvious explanation;
and, screening for visceral leishmaniasis using a recom-
binant K39-antigen strip test IT-LEISH® (Bio-Rad) and
confirmed by Giemsa stained splenic smear.
Urine from all women < 45 years of age was tested for
human chorionic gonadotropin (hCG) using a HCG
Pregnancy Strip Test (Nantong Egens Biotechnology,
Jiangsu, China).
Abdominal imaging
Abdominal ultrasonography was undertaken to a pre-
determined standard by a local radiologist using a
3.5 MHz convex transducer Flexus SSD-1100 (Aloka,
Tokyo, Japan). The diagnosis of CLD was based on the
presence of an irregular liver surface and/or liver paren-
chyma heterogeneity [19]. The presence of schistosomal
periportal fibrosis was diagnosed using WHO criteria
[20] and re-evaluated by an independent expert.
Determination of the aetiology of the CLD
Historical, clinical, laboratory and imaging data were
used to identify the aetiology of the underlying CLD
using published criteria (Table 1) [21–25].
Liver biopsy and histopathology
It was intended that all patients in whom the aetiology of
the CLD remained unexplained following investigation
would be offered a liver biopsy. However, during the
period April 2015 to April 2016, no suitably trained
personnel were available to undertake this procedure. This
situation was eventually resolved and the patients were
subsequently contacted and asked to return for liver bi-
opsy. In the interim several of the more decompensated
patients had died and as the biopsies were to be per-
formed percutaneously, only those with a normal or mar-
ginally elevated prothrombin time were considered
suitable [26].
The procedure was performed, under ultrasound guid-
ance, using a sterile Menghini technique with local an-
aesthetic and a 17G needle Hepafix® (Braun, Melsungen,
Germany). Serial four μm sections were cut and stained
with haematoxylin and eosin; Gomori (reticulin); van
Gieson (collagen); Masson Trichrome (metachromatic);
periodic acid-Schiff (PAS), with and without diastase
(glycogen); and Perls (iron). Histopathologists in Norway
and London independently assessed the histological
findings blinded to the clinical information; inflamma-
tion and fibrosis were graded and staged using the semi-
quantitative, modified Histological Activity Index [27].
Subsequent immunohistochemistry was undertaken
using Ki-67 as a proliferation marker (Dako, catalogue
number M724, concentration 1/100 with pre-treatment)
and activated caspase-3, (Cell Signalling Technology,
catalogue number 9664, concentration 1/100 with pre-
treatment) as an apoptotic marker. Image analysis to
quantify the degree of fibrosis and to calculate the colla-
gen proportionate area (CPA) was carried out on scanned,
Sirius Red stained sections [28].
Statistical methods
Statistical analyses were performed in SPSS 23.0 (SPSS
Inc., Chicago, IL, USA). Categorical variables were sum-
marized as frequencies, while continuous variables were
presented as median and interquartile range (IQR).
Comparisons between groups were performed using the
Pearson χ2-test for categorical variables and Mann-
Whitney U-test for continuous variables. A p-value < 0.05
was considered significant. The Strengthening the Report-
ing of Observational studies in Epidemiology (STROBE)
statement guidelines were followed [29].
Ethics
The study was approved by the National Research Ethics
Review Committee (Ref. No.: 3.10/829/07 and 3.10/129/
2016) in Ethiopia and by the Regional Committees for
Medical and Health Research Ethics (Ref. No.: 2014/
1146) in Norway. The study was conducted in accord-
ance with the Declaration of Helsinki [30]. Written in-
formed consent was obtained from all participating
individuals.
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Results
Study population
A total of 244 patients with liver disease were admitted
to hospital during the study period. Of these, 212 pa-
tients presented with a new diagnosis of probable CLD
and were evaluated for inclusion. The final study popula-
tion comprised of 150 cases with newly diagnosed CLD
(Fig. 1).
Aetiological spectrum
The aetiology of the liver disease was identified in 67
(44.7%) of the 150 patients and ascribed to chronic
HBV infection in 55 (36.7%); hepatic schistosomiasis
in four (2.7%); alcohol misuse in three (2.0%); chronic
HCV infection in two (1.3%); autoimmune hepatitis in
two (1.3%) and visceral leishmaniasis in one (0.7%).
No cause was identified in the remaining 83 (55.3%)
patients, in whom the liver disease was, therefore,
unexplained.
Demography
Overall, there were more men (72.0%) than women; the
median age was 30 (IQR 25–40) years (Table 2). The
majority of the study subjects were Muslim (92.7%). The
overall reported prevalence of daily khat use was 78.0%.
Khat use was more common among men than
women (92.6% vs. 40.5%; p < 0.001); overall khat
exposure was also higher in men than women (36 vs.
0.6 khat-years; p < 0.001).
Women were more likely to have unexplained CLD
than men (71.4% vs. 49.1%; p = 0.013). Otherwise
there were no significant differences in demographic
features between the aetiology known/unknown
groups.
Clinical presentation
The majority of the patients presented with clinical fea-
tures suggestive of hepatic decompensation (Table 3).
Patients with unexplained CLD were more likely to
Table 1 Criteria used to assign the aetiology of the liver disease
Aetiology Criteria used to assign diagnosis
1 Chronic hepatitis B infection Evidence of CLD on liver ultrasound and positive serum HBsAg.
2 Chronic hepatitis C infection Evidence of CLD on liver ultrasound and positive serum anti-HCV and positive HCV RNA.
3 Chronic hepatitis D infection Chronic hepatitis B infection and positive serum anti HDV IgG confirmed by detection of HDV RNA.
4 Primary biliary cholangitis i. Strongly positive anti-mitochondrial antibodies and
ii. Cholestatic liver function tests:
a. ALP > 1.5 x URR and
b. AST < 5 x URR
5 Autoimmune hepatitisa i. Strongly positive anti-nuclear antibodies or anti-actin and
ii. Elevated IgG > 1.1 x URR
6 Alcoholic liver disease i. Clinical and radiological signs of CLD and
ii. Daily alcohol consumption > 20 g/day in women and > 30 g/day in men for 6 months or more.
7 Non-alcoholic fatty liver disease i. Liver ultrasound findings of steatosis and
ii. Absence of significant alcohol consumptionb or other recognised secondary causes of steatosis and
iii. BMI > 25 kg/m2 c
8 Haemochromatosis i. Transferrin saturation > 50% and
ii. Genotyping showing C282Y homozygosity or C282Y/H63D heterozygosity or C282Y/S65C
heterozygosity on the HFE gene.
9 Wilson’s disease i. Serum caeruloplasmin < 0.140 g/L and
ii. Age < 40 years
10 Alpha-1-antitrypsin deficiency Serum alpha-1-antitrypsin level < 0.85 g/L.
11 Malaria Positive malaria rapid diagnostic test and positive microscopy.
12 Hepatic schistosomiasis Presence of ova from Schistosoma mansoni in Kato-Katz thick stool smears and typical liver ultrasound
findings viz. periportal thickening/‘pipestem’ fibrosis confirmed by an independent expert.
13 Visceral leishmaniasis Ultrasound findings of hepatosplenomegaly and
positive K39 antigen strip test confirmed by positive splenic smear.
14 Unexplained chronic liver disease None of the above
Abbreviations: ALP alkaline phosphatase, anti-HCV hepatitis C virus antibody, anti-HDV hepatitis D virus antibody, AST aspartate aminotransferase, BMI body mass
index, CLD chronic liver disease, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, HDV hepatitis D virus, HFE high iron Fe, IgG immunoglobulin G,
URR upper reference range
Laboratory reference ranges: ALP (60–306 U/L); AST (14–40 U/L); IgG (0.8–27.8 g/L) [21]
aBased on the American Association for the Study of Liver Disease (AASLD) simplified criteria [22] in the absence of histology
bAlcohol consumption < 20 g/day in women and < 30 g/day in men
cNot a part of the AASLD criteria [23] but adopted to exclude cases of starvation-induced steatosis
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present with abdominal swelling than those in whom the
aetiology was known (92.8% vs. 76.1%; p = 0.004).
Otherwise there were no distinguishing clinical features
between the aetiology known/unknown groups.
Laboratory findings
Overall, the alterations in laboratory variables were mild
(Table 4). A total of 92 (61.7%) patients had an APRI
score of > 0.7 while 43 (28.9%) had a FIB-4 score of >
3.25. Patients with unexplained CLD had a lower median
serum ALT activity (30 U/L [IQR 21–51] vs. 41 [IQR
Fig. 1 Study flow diagram illustrating the selection of the study
subjects. Abbreviations: CLD, chronic liver disease
Table 2 Demographic features of the study subjects with
chronic liver disease, by aetiology
Variable All patients
(n = 150)
Aetiology
known
(n = 67)
Aetiology
unknown
(n = 83)
Sex (n, % men) 108 (72.0) 55 (82.1) 53 (63.9)*
Age (years) 30 (25–40) 30 (20–40) 30 (25–40)
Ethnic group
Oromo 134 (89.3) 59 (88.1) 75 (90.4)
Amhara 9 (6.0) 5 (7.5) 4 (4.8)
Somali 5 (3.3) 2 (3.0) 3 (3.6)
Gurage 2 (1.3) 1 (1.5) 1 (1.2)
Religion
Islam 139 (92.7) 60 (89.6) 79 (95.2)
Christianity 11 (7.3) 7 (10.4) 4 (4.8)
Occupation
Farmer 100 (66.7) 46 (68.7) 54 (65.1)
Unemployed 14 (9.3) 5 (7.5) 9 (10.8)
Housewife 11 (7.3) 2 (3.0) 9 (10.8)
Student 8 (5.3) 5 (7.5) 3 (3.6)
Day worker 5 (3.3) 3 (4.5) 2 (2.4)
Public servant 4 (2.7) 1 (1.5) 3 (3.6)
Health professional 2 (1.3) 2 (3.0) 0
Other 6 (4.0) 3 (4.5) 3 (3.6)
Pregnant 3 (2.0) 1 (8.3) 2 (6.7)
Previous blood transfusion 23 (15.3) 9 (13.4) 14 (16.9)
Family history of liver disease 8 (5.3) 4 (6.0) 4 (4.8)
Dietary grain stored underground 53 (35.3) 25 (37.3) 28 (33.7)
Weeks of storage 24 (12–52) 24 (12–52) 24 (12–52)
Traditional herbal medicine 40 (26.7) 16 (23.9) 24 (28.9)
History of alcohol consumption:
Never 139 (92.7) 61 (91.0) 78 (94.0)
Current 6 (4.0) 5 (7.5) 1 (1.2)
Stopped 5 (3.3) 1 (1.5) 4 (4.8)
Alcohol abusea 3 (2.0) 3 (4.5) 0
History of daily use of khat 117 (78.0) 56 (83.6) 61 (73.5)
Khat-yearsb 20 (3–70) 20 (3–75) 18 (1–60)
Data are presented as number (%) or as median (interquartile range) unless
otherwise noted
*p < 0.05; significance of the difference between the aetiology
known/unknown group
aDaily consumption of > 20 g/day in women and > 30 g/day in men for
6 months or more
bOne khat-year is defined as daily use of 200 g fresh khat for 1 year
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24–58]; p = 0.032) and values above the upper reference
range (URR) were observed in proportionately fewer
patients than amongst those in whom the aetiology was
known (31.3% vs. 50.7%; p = 0.016). Otherwise there
were no distinguishing laboratory features between the
aetiology known/unknown groups.
Abdominal ultrasound findings
The commonest findings on liver ultrasound were an ir-
regular/nodular liver surface (68.0%), coarse liver texture
(58.0%) and ascites (92.0%) (Table 3). There were no
significant differences in abdominal ultrasound findings
between the aetiology known/unknown groups.
Histopathology
Of the 83 patients with unexplained CLD, 15 (18.1%)
died during or shortly after admission; 35 (42.2%) could
not be contacted; four (4.8%) refused to undergo the
procedure, while 24 (28.9%) were unsuitable because of
a severe coagulopathy. Thus, only five (6.0%) patients
Table 3 Clinical characteristics and ultrasound findings in the
study subjects with chronic liver disease, by aetiology
Variable All patients
(n = 150)
Aetiology
known
(n = 67)
Aetiology
unknown
(n = 83)
Symptoms
Abdominal swelling 128 (85.3) 51 (76.1) 77 (92.8)*
Epigastric pain 12 (80.0) 56 (83.6) 64 (77.1)
Weight loss 119 (79.3) 54 (80.6) 65 (78.3)
Fever 77 (51.3) 35 (52.2) 42 (50.6)
Arthralgia/myalgia 75 (50.3)a 33 (49.3) 42 (51.2)a
Nausea 69 (46.3)a 30 (45.5)a 39 (47.0)
Diarrhoea 64 (42.7) 27 (40.3) 37 (44.6)
Haematemesis 53 (35.3) 27 (40.3) 26 (31.3)
History of jaundice 47 (31.3) 24 (35.8) 23 (27.7)
Clinical findings
Ascites 138 (92.0) 60 (89.6) 78 (94.0)
Splenomegaly 99 (66.0) 48 (71.6) 51 (61.4)
Jaundice 28 (18.7) 16 (23.9) 12 (14.5)
Caput medusae 25 (16.7) 8 (11.9) 17 (20.5)
Hepatic encephalopathy 16 (10.7) 7 (10.4) 9 (10.8)
Traditional scarring/burning 101 (67.3) 46 (68.7) 55 (66.3)
Ultrasound findings
Ascites 138 (92.0) 60 (89.6) 78 (94.0)
Smooth liver surface 4 (2.7) 3 (4.5) 1 (1.2)
Mild uneven liver surface 44 (29.3) 15 (22.4) 29 (34.9)
Nodular liver surface 102 (68.0) 49 (73.1) 53 (63.9)
Heterogeneous echotexture 62 (41.3) 22 (32.8) 40 (48.2)
Coarse echotexture 87 (58.0) 44 (65.7) 43 (51.8)
Hepatic steatosis 1 (0.7) 1 (1.5) 0
Periportal fibrosis 21 (14.0) 9 (13.4) 12 (14.5)
In-hospital death 9 (6.0)a 4 (6.0) 5 (6.1)a
Data are presented as number (%) or as median (interquartile range) unless
otherwise noted
aOne observation missing
*p < 0.05; significance of the difference between the aetiology
known/unknown group
Table 4 Laboratory findings in the study subjects with chronic
liver disease, by aetiology
Laboratory
variable
All patients
(n = 150)
Aetiology
known
(n = 67)
Aetiology
unknown
(n = 83)
ALT (U/L) 34 (22–55) 41 (24–58) 30 (21–51)*
> URR 60 (40.0) 34 (50.7) 26 (31.3)*
AST (U/L) 44 (28–81) 52 (31–83) 41 (28–78)
> URR 84 (56.0) 41 (61.2) 43 (51.8)
ALP (U/L) 317 (207–416) 315 (250–423) 320 (200–385)
> URR 80 (53.3) 37 (55.2) 43 (51.8)
GGT (U/L) 29 (19–48) 29 (21–47) 29 (18–52)
> URR 30 (20.0) 14 (20.9) 16 (19.3)
Total bilirubin (μmol/L) 19 (10–38) 21 (12–51) 17 (10–31)
> URR 36 (24.0) 20 (29.9) 16 (19.3)
Albumin (g/L) 37 (28–50) 36 (30–50) 37 (27–50)
< LRR 63 (42.0) 27 (40.3) 36 (43.4)
Creatinine (μmol/L) 80 (62–97) 80 (62–97) 71 (62–88)
> URR 23 (15.3) 11 (16.4) 12 (14.5)
< LRR 19 (12.7) 8 (11.9) 11 (13.3)
Platelet count (109/L) 125 (76–206) 123 (71–186) 147 (76–223)
< LRR 75 (50.0) 36 (53.7) 39 (47.0)
IgG (g/L) 23.9 (17.1–32.5) 27.0 (16.7–34.2) 21.6 (17.2–30.6)
> URR 55 (36.7) 31 (46.3) 24 (28.9)
HIV infectiona 4 (2.7) 1 (1.5) 3 (3.6)
Kato-Katz smear
positive
23 (16.5)b 13 (21.3)c 10 (12.8)d
APRI score > 0.7e 92 (61.7)f 46 (69.7)f 46 (55.4)
FIB-4 score > 3.25g 43 (28.9)f 20 (30.3)f 23 (27.7)
APRI score > 0.7 OR
FIB-4 score > 3.25
94 (63.1)f 46 (69.7)f 48 (57.8)
Data are presented as number (%) or as median (interquartile range)
Laboratory reference ranges: ALT (8–40 U/L); AST (14–40 U/L); ALP (60–306
U/L); GGT (7–61 U/L); Bilirubin (3–38 μmol/L); Albumin (35–52 g/L); Creatinine
(47–109 μmol/L); Platelet count (126–438 × 109/L); IgG (0.8–27.8 g/L) [21]
aOne patient with chronic HCV was co-infected with HIV.
bStool sample missing in 11 patients.
cStool sample missing in six patients.
dStool sample missing in five patients.
eAPRI: (AST (U/L)/URR of AST (U/L))/platelet count (109/L) × 100
fOne observation missing.
gFIB-4: age (years) x AST (U/L)/(platelet count (109/L) x √ALT (U/L))
*p < 0.05; significance of the difference between the aetiology
known/unknown group
Abbreviations: ALP alkaline phosphatase, ALT alanine aminotransferase,
APRI aspartate aminotransferase to platelets ratio index, AST aspartate
aminotransferase, GGT gamma-glutamyltransferase, HCV hepatitis C virus,
HIV human immunodeficiency virus, IgG immunoglobulin G, LRR lower refer-
ence range, URR upper reference range
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underwent liver biopsy a median (range) of 33 (20–64)
weeks after their initial hospitalization (Table 5); three
(Cases 1/2/4) had a history of khat chewing.
Microscopically none of the specimens showed more
than mild fibrosis and inflammation (Table 6). Foci of
pale stained swollen hepatocytes were identified in Cases
1–4, with no marked zonal distribution; these stained
negative for PAS and were thus suggestive of toxic injury
(Case 1; Fig. 2a-f ). The fifth patient showed no evidence
of adaptive parenchymal changes but mild mixed steatosis
and focal single cell necrosis (Fig. 2g-h). Although the
numbers were modest and the differences small, the prolif-
eration index, apoptotic scores and the CPA tended to be
higher among the three patients (Cases 1/2/4) who chewed
khat compared to the two who did not (Cases 3/5).
Discussion
This study aimed to explore the aetiological spectrum
and underlying risk factors for the development of CLD
in eastern Ethiopia. Chronic HBV infection was the
major identified risk factor, explaining the development
of CLD in roughly one-third of the patients. However,
an aetiological factor was identified in less than 10% of
the remainder. Thus, in over half of the included cases
the aetiology of the liver disease was unexplained.
Of prime importance in this study was the surety of
the diagnosis of CLD. The criteria used were stringent
and required not only that patients had clinical evidence
of decompensated liver disease but also evidence of
hepatic parenchyma heterogeneity and/or surface irregu-
larity on ultrasound. The liver function test abnormal-
ities were mild but this is not incompatible with the
diagnosis of CLD. Over two-thirds of the patients had
APRI and/or FIB-4 scores compatible with a diagnosis of
significant fibrosis/cirrhosis. The histological findings in
the five patients who underwent liver biopsy would seem
at odds with a diagnosis of CLD; however, these patients
fulfilled the inclusion criteria at presentation and biop-
sies undertaken after a considerable delay still showed
evidence of ongoing disease. Thus, the fact that the pa-
tients included in this study had CLD can be accepted
with a high degree of certainty.
The proportion of patients, in the present study, in
whom the CLD was aetiologically unexplained is sub-
stantially higher than might be expected. In the 1980’s
more than 50% of cases of CLD worldwide did not have
an ascribed cause compared with the current global esti-
mate of approximately 5% [31–33]. Thus, the prevalence
of unexplained CLD in this area of eastern Ethiopia is
ten-fold higher than would be expected. No observa-
tional studies exploring the aetiological spectrum of
CLD in eastern Ethiopia or in sub-Saharan Africa are
available for comparison.
The seroprevalence of HBsAg in the present popula-
tion was high while the seroprevalence of anti-HCV was
low. There are no representative population-based
prevalence studies on viral hepatitis in this part of
Ethiopia. However, a recent study of blood donors in
eastern Ethiopia found similar seroprevalence rates to
those reported here [34].
No data are available on the prevalence of NAFLD in
Ethiopia although it is known that Ethiopia has one of
the lowest prevalence rates of obesity worldwide [35].
The data that are available from other populations sug-
gest that the overall prevalence of NAFLD in sub-
Saharan Africa is low [36]. In a case-control study
undertaken in Nigeria, 16.7% of patients with type II dia-
betes mellitus were found to have NAFLD compared
with only 1.2% of non-diabetic control subjects, suggest-
ing that, in comparison with Caucasian, Indian and
Asian populations, diabetes may be a more important
risk factor for NAFLD in Africa than obesity [37]. None
of the patients in the present study was obese; other
than one case with alcoholic liver disease, none had sig-
nificant steatosis on hepatic ultrasound and only one
had diabetes. Thus, the prevalence of NAFLD in this
study population is likely to be very low.
The prevalence of daily khat use identified in the
present study was much higher than previously reported
[11, 13]. A regional study in Harar city found that 20.9%
of 1890 secondary school students chewed khat daily;
the lifetime prevalence of khat chewing was 24.2% [11].
The 2011 Ethiopian Demographic and Health Survey
identified an overall prevalence of khat chewing of
15.3%. However, there are significant regional variations
in the prevalence from 53.2% in the Harari region in
eastern Ethiopia to 1.1% in the Tigray region in northern
Ethiopia [13]. Khat use is more widespread amongst
Muslims than Christians and amongst men than in
women [11, 13], which accords with the findings in the
present study.
There are a number of case reports which implicate
khat as a factor in the development of both acute [38]
and chronic liver disease [39–41]. In addition, khat-
related hepatotoxicity has been convincingly demon-
strated in animal models [42]. The fact that khat use was
similar amongst patients with and without other risk fac-
tors indicated that it may act as a sole or an adjuvant
cause of liver injury. Although only a limited number of
liver biopsies was undertaken, the histological findings
of focal parenchymal changes mirror those observed in
animal models [42] and are supportive of toxic liver in-
jury. However, the design of this study does not allow a
definitive conclusion to be made, and further studies to
assess causality are needed.
This study had a number of strengths despite the
resource limitations at the Ethiopian sites. First: the
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sample size was large and the prospective inclusion of
study subjects provided consistent data sampling
throughout the study period. Second: robust clinical, la-
boratory and ultrasound criteria were used to define
CLD. Third: the aetiology of the liver injury was deter-
mined following a comprehensive, standardized clinical
evaluation, multicentre laboratory testing using high-
performance diagnostics, abdominal ultrasound with ex-
pert review, and, in a small number, histological examin-
ation of liver biopsy material.
The study also has its limitations. First: selection bias
cannot be excluded, as an unknown proportion of pa-
tients with CLD may not have been seen by the recruit-
ing medical services for a variety of practical, cultural
and socioeconomic reasons. Second: liver biopsies were
undertaken in only a small number of patients with un-
explained CLD; the selection procedure for liver biopsy
undoubtedly favoured those with the mildest disease and
the time interval between presentation and the proced-
ure was sufficiently long for there to have been some
resolution of the liver disease. Nevertheless, the histo-
logical findings provided useful confirmatory evidence of
toxic liver injury in some. Third: issue could be taken
with the criteria used to diagnose schistosomal liver
disease. Positive assignment required a positive stool
smear and radiological evidence of periportal thicken-
ing/‘pipe stem’ fibrosis confirmed by expert opinion;
thus, the diagnosis may have been underestimated.
Fourth: HBV DNA levels were not measured in 95
HBsAg-negative patients and thus the presence of occult
HBV could not be ruled out in this subgroup [43].
However, the pathogenetic mechanism of occult HBV
infection is still not clear [44] and the role of occult
HBV in unexplained CLD is still debated [33]. Approxi-
mately 95% of the patients with unexplained CLD in the
present study had decompensated disease on presentation
but only low-grade abnormalities in the liver transaminase
activities. Thus, it is unlikely that occult HBV infection
was the underlying cause of the unexplained CLD in this
population. Finally: the diagnosis of CLD was not con-
firmed by advanced imaging, endoscopy or, in the major-
ity, by histological examination of liver biopsy material.
Furthermore, certain causes of CLD could not be ruled
out due to resource limitations, including: primary scler-
osing cholangitis, veno-occlusive disease/Budd-Chiari syn-
drome and injury from other hepatotoxins.
CLD has recently been reported as the leading cause of
death in adults less than 50 years of age in eastern
Table 6 Histopathological findings of the five patients with unexplained chronic liver disease who underwent liver biopsy
No Sex Age (yr) General microscopy Parenchymal changes Ishak-score
1 Female 26 Mild portal and lobular hepatitis with
sinusoidal lymphocytosis. Variation of
hepatic cord thickness.
Normal bile ducts and intact liver plate.
Focal adaptive parenchymal changes with
diffuse hepatocyte swelling/ clarification.
No steatosis or haemosiderosis.
Collagen proportionate area: 5%
Proliferation index: 8%
Apoptosis index: 3%
Fibrosis = 2
Necroinflammation = 2
• piecemeal 0
• lobular 1
• confluent 0
• portal 1
2 Male 25 Normal architecture with normal portal
areas, no inflammation. Normal bile ducts
and intact liver plate.
Adaptive parenchymal changes with diffuse
hepatocyte swelling/ clarification. No
steatosis or haemosiderosis.
Collagen proportionate area: 6%
Proliferation index: 12% Apoptosis index: 5%
Fibrosis = 1
Necroinflammation = 0
3 Female 30 Normal architecture with normal portal
areas, no inflammation. Normal bile ducts
and intact liver plate.
Mild adaptive parenchymal changes with
diffuse hepatocyte swelling/clarification. No
steatosis or haemosiderosis.
Collagen proportionate area: 3%
Proliferation index: 6% Apoptosis index: 1%
Fibrosis = 1
Necroinflammation = 1
• piecemeal 0
• lobular 1
• confluent 0
• portal 0
4 Male 25 Normal architecture with normal portal
areas, no inflammation. Normal bile ducts
and intact liver plate.
Adaptive parenchymal changes with diffuse
hepatocyte swelling/clarification. No
steatosis or haemosiderosis.
Collagen proportionate area: 8%
Proliferation index: 15% Apoptosis index: 6%
Fibrosis = 0
Necroinflammation = 0
5 Female 25 Normal architecture with normal portal
areas. Normal bile ducts and intact liver
plate
Mild mixed steatosis ≈ 20% Focal single cell
necrosis, a few apoptotic hepatocytes, a few
parenchymal granulocytes. No adaptive
changes.
Collagen proportionate area: 3%
Proliferation index: 3% Apoptosis index: 2%
Fibrosis = 0
Necroinflammation = 1
• piecemeal 0
• lobular 1
• confluent 0
• portal 0
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Ethiopia [9]. If, as identified in the present study, a high
proportion of the CLD is ‘unexplained’ then it may be dif-
ficult, if not impossible, to prevent its occurrence and
hence to reduce the burden it imposes. If, however, as sug-
gested in the present study, exposure to the recreational
substance khat is of major aetiological importance, then
there is an urgent need to further investigate this possibil-
ity with analytic studies designed to assess causality. There
are campaigns in place to radically reduce the burden of
viral liver disease worldwide [45], and this is undoubtedly
vital. However, if khat was found to be a major contributor
to the development of CLD, then given its widespread use,
Fig. 2 Liver histology in Ethiopian patients with unexplained chronic liver disease. a Case 1: Adaptive parenchymal changes with focal diffuse
swollen pale stained hepatocytes stretching through all zones. H&E, 100×. b Case 1: Intact liver plate, normal bile ducts and patent central vein.
Sinusoidal lymphocytosis. H&E, 200×. c + d Case 1: Masson Trichrome stain negative indicated non-cirrhotic liver disease. 100×, 200×. e + f Case 1:
Swollen hepatocyte clarification negative for periodic acid-Schiff stain in approximately 30%. 200×. g Case 5: Mild mixed steatosis. H&E, 100×.
h Case 5: Mixed macro- and microvesicular steatosis with focal single cell necrosis and sporadic parenchymal granulocytes. H&E, 400×.
Abbreviations: H&E, haematoxylin and eosin
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legal status and social acceptability it would be a much
more difficult problem to deal with requiring concerted
governmental action in the countries and communities
involved.
Conclusions
Chronic HBV infection was found in around one third
of patients hospitalized with CLD in eastern Ethiopia.
However, in over half of the patients the aetiology of the
liver disease was unexplained. The prevalence of khat
chewing was much higher in the CLD population than
expected, suggesting khat as an effect modifier and/or
independent risk factor for development of CLD in this
part of the world. Further epidemiological studies, which
include appropriate comparison groups, should be
undertaken to assess whether khat plays a causal role in
the development of CLD.
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